Distribution of low-density lipoprotein and high-density lipoprotein subclasses in patients with sarcoidosis

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 12, 2013, Pages 1780-1787

  Vekic, Jelena ^a   Zeljkovic, Aleksandra ^a   Jelic Ivanovic, Zorana ^a   Spasojevic Kalimanovska, Vesna ^a   Spasic, Slavica ^a   Videnovic Ivanov, Jelica ^a   Ivanisevic, Jasmina ^a   Vucinic Mihailovic, Violeta ^a   Gojkovic, Tamara ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892742319     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0299-OA     Document Type: Article

References (34)

1. Ginsberg HN, Le NA, Gilbert HS. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 1986;35(9):878-882.
2. Ginsberg HN, Goldberg I, Wang-Iverson P, et al. Increased catabolism of native and cyclohexanedione modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis. 1983;3(3):233-241.
3. Chen ES, Moller DR. Sarcoidosis: scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7(8):457-467.
4. Kindman LA, Gilbert HS, Almenoff JS, Ginsberg H, Fagerstrom R, Teirstein AS. High-density lipoprotein cholesterol is reduced in patients with sarcoidosis. Am J Med. 1989;86(4):376-378.
5. Salazar A, Maña J, Pinto X, et al. Low levels of high density lipoprotein cholesterol in patients with active sarcoidosis. Atherosclerosis. 1998;136(1):133-137.
6. Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab. 2009;55(11-12):421-429.
7. Olusi SO, George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc Health Risk Manag. 2011;7:75-80.
8. Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-näive patients with early rheumatoid arthritis. Atherosclerosis. 2009;207(2):502-506.
9. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27(2):174-182.
10. Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004;164(5):551-556.
11. Ardic I, Yarlioglues M, Dogdu O, et al. Assessment of aortic elastic properties in patients with sarcoidosis. Blood Press. 2012;21(5):286-292.
12. Ivanišević J, Kotur-Stevuljević J, Stefanović A, et al. Dyslipidemia and oxidative stress in sarcoidosis patients. Clin Biochem. 2012;45(9):677-682.
13. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012;12:41-49.
14. Salazar A, Mañá J, Pintó X, Argimón JM, Hurtado I, Pujol R. Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Clin Chim Acta. 2002;320(1-2):59-64.
15. Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am. 2011;40(2):409-417.
16. The joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160(2):736-755.
17. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(6):227-239.
18. Rainwater DL, Moore PH, Gamboa IO. Improved method for making nondenaturing composite gradient gels for the electrophoretic separation of lipoproteins. J Lipid Res. 2004;45(4):773-775.
19. Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem. 2007;40(5-6):310-316.
20. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis. 2010;210(2):548-554.
21. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, et al. Characteristics of low-density and high-density lipoprotein subclasses in pediatric renal transplant recipients. Transpl Int. 2011;24(11):1094-1102.
22. Byrne CD. Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Atherosclerosis. 1999;145(1):1-15.
23. Van J, Pan J, Charles MA, Krauss R, Wong N, Wu X. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med. 2007;131(11):1679-1685.
24. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010;208(1):3-9.
25. Salazar A, Maña J, Fiol C, et al. Influence of serum amyloid A on the decrease of high density lipoprotein-cholesterol in active sarcoidosis. Atherosclerosis. 2000;152(2):497-502.
26. Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 1988;85(5):632-638.
27. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104(16):1887-1893.
28. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997;24(3):445-451.
29. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based casecontrol study. Heart. 2004;90(8):859-865.
30. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol. 2012;8(1):95-103.
31. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141(1):154-162.
32. Gilbert S, Steinbrech DS, Landas SK, Hunninghake GW. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Resp Dis. 1993;148(2):483-486.
33. Grunewald J, Eklund A. Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc. 2007;4(5):461-464.
34. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation. 2003;108(2):161-165.